Medicine
Depo-SubQ Provera 104 mg/0.65 mL injectable suspension
Depo-SubQ Provera 104 mg/0.65 mL injectable suspension is a prescription medicine containing Medroxyprogesterone for subcutaneous use, marketed by Pharmacia & Upjohn, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not refrigerate. Store at controlled room temperature 20° C to 25° C (68° F…
Key facts
- Active ingredient (INN)
- Medroxyprogesterone
- Brand
- Depo-SubQ Provera
- Strength
- 104 mg/0.65 mL
- Dosage form
- Injectable suspension
- Route
- Subcutaneous
- Packs
- 1 syringe of 0.65 mL
- Marketing authorisation holder
- Pharmacia & Upjohn
- Manufacturer
- Pharmacia & Upjohn
- Origin register
- US FDA, United States
- Storage
- Do not refrigerate. Store at controlled room temperature 20° C to 25° C (68° F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G03AC06 Medroxyprogesterone
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 May 2005
- Identifiers
- RxCUI 1000156, 1000158DailyMed set ID 390087a6-f3c3-4f0b-a930-79acf412f153NDC 0009-4709Application NDA021583
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe in 1 carton / .65 mL in 1 syringe | 0009-4709-13 | Pharmacia & Upjohn | 2 May 2005 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 June 1959 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Medroxyprogesterone
Clinical summary
Medroxyprogesterone is a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. MedsAcross supplies Medroxyprogesterone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MedroxyprogesteroneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Provera prescribing information (Pharmacia & Upjohn) · U.S. National Library of Medicine, DailyMed
Need Depo-SubQ Provera 104 mg/0.65 mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.